Solving the 'Parking' Problem in the Drug Monopoly Game
The Hill (December 2019)
3 Pages Posted: 2 Jun 2020
Date Written: December 27, 2019
Drug prices are too high. One reason is that brand-name drug firms delay generic entry. Another is that generic companies themselves delay entering the market. And they delay not only their entry but those of other generics as well.
Congress is considering addressing this “parking” of generic exclusivity. One proposal, the BLOCKING Act of 2019, would not solve the problem. Another, the Expanding Access to Low-Cost Generics Act, co-sponsored by Senators Smith and Braun, would. This op ed explains how.
Keywords: settlements, generics, Hatch-Waxman Act
JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38
Suggested Citation: Suggested Citation